Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …

Background The risk of stroke varies considerably across different groups of patients with
atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is associated with an increased …

This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the American
College of Chest Physicians Evidence-Based Guidelines Clinical Practice Guidelines (8th …

Background Antithrombotic therapy reduces stroke, embolism and mortality in patients with
atrial fibrillation (AF); however, meta-analyses have focused on pairwise comparisons of …

This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the Seventh
ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based …

In recent years the management of atrial fibrillation patients has progressively and
substantially changed because of the introduction of new treatments and the availability of …

Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a
CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging …

Atrial fibrillation (AF) has been gaining much attention as one of the major causes of
cerebral infarction [1]. For practitioners to effectively manage this risk, it is imperative to …

Background Current guidelines strongly recommend that oral anticoagulation should be
offered to patients with atrial fibrillation and≥ 1 stroke risk factors. The guidelines also …

In patients with atrial fibrillation (AF) and an intermediate risk of stroke (CHADS 2 score= 1),
available evidence from clinical trials is inconclusive and the present guidelines for the …